Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06534840

Evaluation of Pulmonary Complications in Liver Transplantation Patients Based on Machine Learning

The main objective of this study is to develop a machine learning model that predicts moderate-severe prediction model of pulmonary complications in liver transplantation patients within 14 postoperative day using a real-world, local preoperative and intraoperative electronic health records, not administrative codes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Postoperative pulmonary complications can increase the length of hospital stay and medical costs. In particular, moderate to severe pulmonary complications, which often require clinical intervention, once occur, will lead to significantly prolonged postoperative hospitalization or even cause permanent damage or death in severe cases. A number of risk-stratified cation models have been developed to identify patients at increased risk of postoperative pulmonary complications. However, these models were built by using the traditional regression analysis. However, the traditional prediction methods have the disadvantages of limited processing power of nonlinear models and outlier, and relatively single selection variables. The obtained models have poor accuracy, and the quantification degree is not enough, so it is difficult to popularize clinical application. Artificial machine learning can use it by analyzing a large number of specific features in the rich data set to identify and learn to accurately predict the diagnosis and prognosis of diseases, and surpass traditional prediction models in dealing with classification problems. The algorithms are flexible, and it is more and more widely used in clinical practice research. However, there are few reports on machine learning models predicting prognostic models related to postoperative pulmonary complications in liver transplantation patients. Therefore, we aimed to build predictive models using artificial machine learning methods to screen for their risk factors in order to provide early intervention and individualized treatment for high-risk patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (age ≥ 18 years)
  • Undergoing liver transplantation

Exclusion criteria

  • Re-transplantation
  • Multi-organ transplants
  • Intra-operative deaths
  • severe encephalopathy (West Haven criteria III or IV)
  • Incomplete clinical data

Treatment and study plan

Primary outcomes

  1. Prediction of postoperative moderate-to-severe pulmonary complications

    Time frame: August 2024-December 2024

    IA total of 72 variables are expected to be included, using 6 types of machine learning methods, including decision tree (DT), logistic regression (LR), random forest (, RF), support vector machine (SVM), extreme gradient lift (XGBoost), and gradient lift decision tree (GBDT) to build a moderate postoperative prediction model

Study contacts

Contact information is provided by the study sponsor or research team.

Chun ling Jiang, PhD

CONTACT

[email protected]

+8602885423593

Sponsors and collaborators

Lead sponsor

West China Hospital

Other

Registry information

Official study title

Establishment and Evaluation of Moderate-severe Prediction Model of Pulmonary Complications in Liver Transplantation Patients Based on Machine Learning Algorithm

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Aug 2, 2024
Registry last updated
Aug 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.